Research Activity
22 States Sue Trump Administration Over Drastic NIH Funding Cuts
NIH funding, indirect costs, research grants, Trump administration, lawsuit, universities, medical research
Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor
Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis (IPF), BEACON-IPF trial, clinical trial suspension, Data Safety Monitoring Board (DSMB)
AI-Driven Discovery Unveils Novel Antimicrobial Proteins Effective Against Bacterial and Fungal Infections in Mice
Artificial intelligence, protein compounds, antimicrobial peptides, drug discovery, bacterial infections, fungal infections, in vivo studies
Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board
Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial
xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research
Pfizer Taps Novartis Veteran Jeffrey Legos to Lead Oncology R&D Efforts
Pfizer, Jeffrey Legos, oncology, R&D, leadership, cancer research, pharmaceutical industry
Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024
Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development
EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies
DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement